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Abstract 
Cocaine addiction is a chronically relapsing disorder that is associated with harmful 
consequences. Relapses occur frequently and effective pharmacotherapies are currently sparse. 
Preclinical studies suggest that altered glutamatergic signaling is crucial for the maintenance of 
cocaine self-administration. However, the translational validity of these models is currently unknown. 
Therefore, we investigated potential differences of glutamate, glutamine, and further metabolite levels 
in the pregenual anterior cingulate cortex (pgACC) and the right dorsolateral prefrontal cortex 
(rDLPFC) of chronic cocaine users and controls using the ProFit 2.0 tool in combination with 2D J-
resolved single-voxel 1H-magnetic resonance spectroscopy at 3T and voxel tissue composition and 
relaxation correction. Glutamate and glutamine levels did not differ between cocaine users and 
controls but higher weekly cocaine use and higher cocaine hair concentrations were associated with 
lower glutamine/creatine ratios in the pgACC. Interestingly, cocaine users exhibited higher 
glucose/total creatine ratios than controls in the pgACC and higher choline/creatine ratios in the 
pgACC and rDLPFC. These results imply that cocaine use is associated with altered cortical glucose 
metabolism and membrane turnover. Finally, cocaine use over the past six months appears to decrease 
cortical glutamine levels indicating changes in glutamate cycling. 
 
Keywords: anterior cingulate cortex, choline, cocaine addiction, glutamate, glutamine, magnetic 
resonance spectroscopy 
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Introduction 
A hallmark of cocaine addiction is the compulsive seeking and taking of cocaine despite the 
occurrence of harmful consequences. Preventing the frequently occurring relapses remains one of the 
most challenging issues in treating cocaine addiction and few effective pharmacotherapies are 
currently available (Hyman & Malenka 2001). The persisting vulnerability to relapse presumably 
arises from conditioning processes where neutral environmental stimuli become associated with 
cocaine-related stimuli and eventually increase the risk for relapse by inducing strong craving urges 
for the drug (Goldstein & Volkow 2011; Volkow et al. 2006). Seminal findings from preclinical 
studies have indicated that alterations in glutamatergic signaling may be of particular importance for 
relapse vulnerability (Gipson et al. 2013; Kalivas 2009). In particular, the glutamatergic projection 
from the prefrontal cortex (PFC) to the nucleus accumbens (NAc) core appears to hold a crucial role in 
mediating drug-seeking in rodents (Kalivas 2009; Sun & Rebec 2006). Accordingly, after extinction 
from repeated cocaine self-administration, the basal burst activity of PFC neurons (Sun & Rebec 
2006) and extracellular glutamate levels in the NAc core were reduced (Baker et al. 2003), and the 
ability to induce synaptic plasticity in NAc medium spiny neurons was markedly impaired in rats 
(Gipson et al. 2013). Contrarily, in response to cocaine-conditioned cues a large increase of synaptic 
glutamate release from prefrontal afferents to the NAc core (McFarland et al. 2003) and rapid, 
transient long-term potentiation (LTP) have been observed, the latter of which was associated with the 
intensity of reinstated cocaine-seeking (Gipson et al. 2013).  
These preclinical findings may parallel findings from neuroimaging studies in humans where 
chronic cocaine users (CU) exhibited reduced glucose metabolism in the PFC during protracted 
abstinence (Volkow et al. 1992). In contrast, PFC activity and dopaminergic changes were strongly 
enhanced upon exposure to drug-associated cues, which was associated with the strength of drug 
craving (Volkow et al. 2006). It has recently been posited that the loss of synaptic plasticity in 
response to nondrug-associated stimuli may be responsible for the difficulty of CU to exert alternative 
and more appropriate behaviors competing with drug relapse, while the LTP induced by drug-
associated stimuli may be linked to the overwhelming desire to procure the drug (Gipson et al. 2013). 
However, to what extent the glutamatergic abnormalities observed during withdrawal and cue-induced 
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drug-reinstatement in rats also occur in human CU is largely unknown. In addition to metabolic 
abnormalities, also structural alterations have been observed in chronic CU including reduced white 
and gray matter volumes particularly in the PFC (Lyoo et al. 2004; Makris et al. 2008). Thus, 
identifying and understanding glutamatergic and other neurometabolic alterations associated with the 
vulnerability to relapse may contribute to the development of novel medications for the treatment of 
cocaine addiction. 
Proton magnetic resonance spectroscopy (1H-MRS) is a suitable technique to non-invasively 
quantify neurotransmitters and neurometabolites in vivo in humans. A number of 1H-MRS studies 
have investigated the combined signal of glutamate and glutamine (Glx), the most abundant excitatory 
neurotransmitter and its metabolic product, or solely glutamate as well as other neurometabolite levels 
in human CU (Chang et al. 1999; Martinez et al. 2013; Schmaal et al. 2012; Yang et al. 2009). 
Regarding glutamatergic abnormalities, prior studies reported both decreased (Yang et al. 2009) and 
increased (Schmaal et al. 2012) glutamate levels in the rostral vs. dorsal anterior cingulate cortex 
(ACC) of CU expressed as glutamate/total creatine (tCr) ratios. Moreover, a recent study quantified 
Glx in the striatum of 15 dependent crack CU, but failed to find significant differences between CU 
and controls (Martinez et al. 2013). Interestingly, a study with non-human primates was able to 
separately resolve glutamate and glutamine in the putamen (Liu et al. 2011). Squirrel monkeys who 
had been exposed to cocaine for nine months exhibited reduced glutamate/tCr levels in the putamen 
after one month, but had increased glutamate/tCr levels after six and nine months and increased 
glutamine/tCr levels after nine months compared to baseline (Liu et al. 2011). Extracellular glutamate 
is normally taken up and converted into glutamine by astrocytes and is subsequently released to be 
taken up and reconverted to glutamate by neurons. Although it is not possible with 1H-MRS to 
distinguish the metabolic from the neurotransmitter pool, separate quantification of glutamate and 
glutamine may provide additional information regarding altered neuroenergetics and glutamate-
glutamine cycling. Further metabolites of interest include γ-aminobutyric acid (GABA), N-
acetylaspartate (NAA), total choline (tCho), and myo-inositol. GABA, the primary inhibitory 
neurotransmitter, and NAA, a putative marker for neuronal function or loss, were decreased in the 
frontal cortex of CU (Ke et al. 2004; Simmons et al. 1991). tCho, implicated in membrane turnover, 
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and myo-inositol, involved in phosphatidylinositol second messenger signaling and osmoregulation, 
have been shown to be increased in CU (Ross 1991). Lower NAA and higher tCho levels could reflect 
the above-mentioned gray and white matter reductions in CU (Lyoo et al. 2004; Makris et al. 2008). 
To reliably detect the main metabolites of interest including glutamate, glutamine, GABA, 
NAA, tCho, and myo-inositol in the pregenual anterior cingulate cortex (pgACC) and the right 
dorsolateral PFC (rDLPFC) in chronic CU and healthy controls (HC), we applied an enhanced version 
of PRior knOwledge FITting tool (ProFit) in combination with two-dimensional (2D) J-resolved 
single-voxel 1H-MRS (Fuchs et al. 2013). For these metabolites, specific hypotheses could be 
generated based on prior studies. We further investigated ten additional exploratory metabolites that 
have not been systematically investigated thus far: N-acetylaspartylglutamate (NAAG), glucose, 
lactate, scyllo-inositol, taurine, glycine, glutathione, phosphoethanolamine, aspartate, and ascorbic 
acid. The pgACC and the rDLPFC were selected as regions-of-interest because of their key 
involvement in cocaine dependence: Chronic CU have been shown to exhibit reduced glucose 
metabolism in the pgACC and DLPFC during sustained withdrawal (Volkow et al. 1992), whereas 
upon the presentation of drug-associated cues increased functional activity of the pgACC has been 
observed (Volkow et al. 2006). The pgACC holds an important role in emotion regulation and is 
assumed to mediate stress reactivity, attentional bias towards drug-associated stimuli, and disrupted 
ability to update the reward value of non-drug reinforcers in addicted drug users (Goldstein & Volkow 
2011). The DLPFC is implicated in top-down control and may be associated with impulsive and 
compulsive behaviors in cocaine-addicted individuals, the processing of negative affect including 
cocaine craving, and enhanced motivation to obtain cocaine opposed to other reinforcers and drug-
related learning (Goldstein & Volkow 2011). 
Based on prior results, we hypothesized that: 1) CU exhibit lower glutamate, glutamine, GABA, 
and NAA concentration ratios and increased tCho and myo-inositol concentration ratios, 2) lower 
glutamate and glutamine concentration ratios are associated with craving scores, duration and quantity 
of cocaine use. A secondary goal was to investigate the influence of potential co-factors on metabolite 
concentration ratios including alcohol and tobacco, and post-acute cocaine and cannabis effects. 
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	 6
Materials and methods 
Subjects 
The study sample comprised 18 male drug-naïve HC and 18 male chronic CU who participated 
in the longitudinal Zurich Cocaine Cognition Study (ZuCo2St)(Hulka et al. 2014a; Preller et al. 2013; 
Vonmoos et al. 2013) including a positron emission tomography (PET) study (Hulka et al. 2014b). 
Inclusion criteria for CU were 1) age 20-50 years, 2) DSM-IV diagnoses of cocaine abuse/dependence 
(Wittchen et al. 1997), 3) no polytoxic drug use and medication affecting the CNS, 4) no current or 
previous Axis I DSM-IV psychiatric disorder (other than cocaine abuse/dependence, alcohol abuse, 
nicotine dependence, history of depression), 5) no family history of a severe psychiatric disorder such 
as schizophrenia, bipolar or obsessive-compulsive disorder, 6) no neurological disorder or head injury, 
and 7) no magnetic resonance imaging (MRI) contraindication. The same inclusion criteria applied to 
the HC except for criterion 2). In addition, HC were excluded if they regularly engaged in illegal drug 
use with exception of cannabis use. Participants were instructed to abstain from illegal drugs for >3 
days and >24 hours from alcohol. Urine samples were collected to control for recent drug use. To 
objectively characterize drug use over the past six months, hair samples (6cm) were collected and 
analyzed with liquid chromatography-mass spectrometry (for details Vonmoos et al. 2013). The study 
was approved by the Ethics Committee of the Canton of Zurich and was carried out in accordance 
with the Declaration of Helsinki. All participants provided written informed-consent before inclusion 
and received financial compensation. 
 
Clinical assessment 
Trained psychologists screened all participants for the presence of Axis-I psychiatric disorders 
using the Structured Clinical Interview for DSM-IV Disorders (Wittchen et al. 1997). Drug use was 
assessed with the Interview for Psychotropic Drug Consumption (for details Vonmoos et al. 2013). 
The Beck Depression Inventory (BDI) was used to assess symptoms of depression (Beck et al. 1961). 
The Symptom Checklist-90-R (SCL-90-R) served as a screening measure of general psychiatric 
symptoms (Franke 1995). The brief version of the Cocaine Craving Questionnaire (CCQ) was applied 
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to measure current cocaine craving (Sussner et al. 2006). The Fagerström Test for Nicotine 
Dependence (FTND)	was used to determine severity of nicotine dependence (Heatherton et al. 1991).  
 
Image acquisition and data analyses 
MRI Acquisition: For each participant, a T1-weighted three-dimensional fast gradient echo MRI 
scan (180 slices, FOV=220mm, matrix=224x224 reconstructed to 256x256, voxel 
size=0.98x0.98x1.5mm) was acquired on a Philips Achieva 3T whole-body scanner equipped with a 
transmit/receive head coil (Philips Healthcare, Best, The Netherlands) to rule out structural 
abnormalities and to place the 1H-MRS voxels of interest. Prior to the MRI and 1H-MRS acquisition, 
all participants underwent a PET scan (Hulka et al. 2014b). 
1H-MRS Acquisition and Processing: Single voxel 1H-MRS data were acquired for the 
predefined volume-of-interest (VOI) of 25x18x20mm3=9.0ml in the bilateral pgACC and the rDLPFC 
(Figure 1A and B) using a birdcage transmit-receive head coil with a maximum B1=20T. In order to 
quantify the main metabolites of interest glutamate, glutamine, GABA, NAA, tCho, and myo-inositol 
as well as ten exploratory metabolites including NAAG, glucose, lactate, scyllo-inositol, taurine, 
glycine, glutathione, phosphoethanolamine, aspartate, and ascorbid acid, a maximum echo-sampled 
2D J-resolved point-resolved spectroscopy (JPRESS) sequence (TR of 1600 ms, TE ranging from 26 
to 224 ms with step size of 2 ms, 100 encoding steps, 8 averages per step) with VAPOR water and 
interleaved inner volume suppression was applied. The improved quantification approach based on 
ProFit 2.0 has been validated elaborately and methodological details are described elsewhere (Fuchs et 
al. 2013). The 1H-MRS acquisitions lasted 22 minutes for each brain region. Prototypical projections 
of 2D J-PRESS spectra including spectral fit and residue of the pgACC and rDLPFC are depicted in 
Figure 1A and B and a 2D JPRESS spectrum of the pgACC including fit and residue in Figure 2. 
Metabolite levels were referenced to tCr (as reported in the main manuscript) and to internal 
water (supplementary information, SI), yielding comparable results, and a segmentation based 
volume tissue composition and relaxation correction was applied for both reference standards creatine 
and water (Gasparovic et al. 2006). Prior 1H-MRS studies did not find significant tCr concentration 
differences between CU and HC (Meyerhoff et al. 1999; Schmaal et al. 2012; Yang et al. 2009). In 
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addition, in our study, the tCr levels in CU and HC did not differ when referenced to internal water 
even after correction for age, smoking status, and gray and white matter volumes (p>.42, see Table 3). 
The following equations, adopted from Gasparovic et al. (2006), were applied for the use of H2O 
(equation 1) and tCr (equation 2) as internal concentration references, with SM_obs standing for 
observed metabolite signal, f for fraction including volume share and tissue type specific concentration 
differences for water (equations 5-7 in Gasparovic et al. 2006) and creatine (equation 3) references, 
GM for gray matter, WM for white matter, CSF for cerebrospinal fluid, and R for relaxation 
attenuation factor including T1 and T2 relaxation correction for water and creatine: 
(1) [Mreferenced to 
H2O]=(SM_obs(fGM_H2ORH2O_GM+fWM_H2ORH2O_WM+fCSF_H2ORH2O_CSF)2x55.51[mol/kg])/(SH2O
_obs(1-fCSF)) 
(2) [Mreferenced to tCr]=SM_obs(fGM_CrRCr_GM+fWM_CrRCr_WM)37.62[mol/kg]/StCr_obs 
(3) fGM_Cr=0.00095*fGM_Vol_Cr1/(fGM_Vol_Cr 0.00095+fWM_Vol_Cr0.00051) 
fWM_Cr=0.00051*fWM_Vol_Cr1/(fGM_Vol_Cr 0.00095+fWM_Vol_Cr0.00051) 
The resulting metabolite concentrations were reported in arbitrary units since only a tissue type non-
specific but individual T2 relaxation correction has been performed by ProFit 2.0 for all reported 
metabolites (Fuchs et al. 2013), but no T1 relaxation correction or correction for the number of 
contributing protons was applied for the metabolites (only for the reference standards) as for most of 
them T1 relaxation times are still unknown. 
The Cramér-Rao lower bounds (CRLBs) served as the quality criterion to determine the 
reliability of the fit for each metabolite peak. Metabolite estimates with CRLBs >20% were excluded. 
Due to movement artifacts or CRLBs >20%, one spectrum of a control subject from the pgACC and 
five spectra of CU from the rDLPFC had to be excluded from the statistical analyses. 
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Statistical analysis 
Statistical analyses were carried out with the PASW 19.0 software (SPSS Inc.). Demographic, 
clinical, and drug use data of the two groups were analyzed with independent T-tests and frequency 
analyses (Pearson’s Chi2-test). Analyses of covariance (ANCOVA) with age, smoking status, gray and 
white matter volumes as covariates were conducted to compare 1H-MRS metabolite levels between the 
two groups. For the main metabolites of interest one-tailed tests were carried out and for the 
exploratory metabolites two-tailed tests. 
 
For the main metabolites of interest, specific hypotheses regarding the direction of the effect 
were derived based on prior data, wherefore one-tailed tests were carried out. For the exploratory 
metabolites two-tailed tests conducted. Potential associations of drug use patterns and clinical 
measures with 1H-MRS metabolite levels were examined with partial correlation analyses (adjusted 
for age). The p-value was set at .05. Drug use parameters (weekly use, last use, cumulative doses) 
were log-transformed as the assumptions of parametric distribution and homoscedasticity were not met 
and the constant 1 was added because the data contained 0 values. Effect sizes (Cohen’s d) were 
calculated with G*Power 3.1 (Faul et al. 2007). 
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Results 
Subject characteristics and drug use patterns 
HC and CU did not differ with regard to age, body mass index, years of education, BDI and 
SCL-90 scores, smoking status, and smoking severity (Table 1). Nine (50%) CU met the DSM-IV 
criteria for current cocaine dependence and nine (50%) CU met the criteria for cocaine abuse. All 
except one CU who smoked cocaine reported to administer the drug nasally. Legal and illegal drug use 
patterns are shown in Table 1 and 2. CU did not differ from HC with regard to tobacco consumption. 
Contrarily, CU reported higher weekly alcohol consumption [t(34)=-2.36, p<.05, d=.79] and higher 
cumulative doses of cannabis [t(34)=-2.18, p<.05, d=.73]. Hair toxicology analyses capturing the past 
six months confirmed that cocaine was the primary drug of choice. Methamphetamine and opiates 
were not detected at all, amphetamine levels were below the threshold of reliable detection >200pg/mg 
(n=3), and MDMA levels were small to moderate (n=6). Notably, urine toxicology analyses revealed 
that 44% of the CU tested positive for recent cocaine use, and 13% of the HC and 33% of the CU 
tested positive for cannabis use. 
 
Tissue composition and regional concentration ratios of the main metabolites 
Groups neither differed with regard to gray matter, white matter, and cerebrospinal fluid 
volumes in the pgACC (p>.35) nor the rDLPFC (p>.14)(Table 3). Concentration ratios for the main 
metabolites of interest of HC and CU are shown in Table 3 (concentration ratios of all metabolites 
referenced to H2O are shown in Table S2). An ANCOVA with age, smoking status, gray matter 
volume, and white matter volume as covariates revealed that in the pgACC, CU showed a higher 
tCho/tCr ratio (d=.54) in comparison to HC. Also in the rDLPFC, CU exhibited a higher tCho/tCr ratio 
(d=.72; Figure 3B) and, additionally, by trend a higher myo-inositol/tCr ratio (d=.60) than HC. No 
significant group differences were observed for glutamate or glutamine levels (Figure 4A-D). 
 
Correlations between drug use patterns and main metabolites  
Only subjects who used the drug of interest were included in the analyses in order to avoid 
spurious correlations. Cocaine use: In the pgACC voxel of CU, higher quantity of weekly cocaine use 
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(r=-.59, p<.05, n=17; Figure 5A) and total cocaine hair concentration (r=-.57, p<.05, n=17; Figure 
5B) were associated with lower glutamine/tCr ratios. In the rDLPFC voxel, higher weekly cocaine use 
(r=-.67, p<.05, n=13; Figure 5C) and total cocaine hair concentration (r=-.64, p<.05, n=13; Figure 
5D) were associated with lower myo-inositol/tCr ratios. Alcohol use: In the pgACC, longer alcohol 
abstinence duration was associated with higher GABA/tCr ratios (r=.61, p<.01, n=19). In the rDLPFC, 
longer alcohol abstinence duration was associated with lower tCho/tCr ratios (r=-.37, p<.05, n=31). 
No significant correlations were found between brain metabolite concentrations and tobacco or 
cannabis use parameters. 
 
Correlations between demographic/clinical measures and main metabolites 
In the pgACC voxel, older age was associated with a lower glutamine/tCr ratio (r=-.42, p<.05, 
n=34) and higher scores of the global severity index in the SCL-90 were associated with higher 
tCho/tCr ratios (r=.37, p<.05, n=35). In the rDLPFC voxel, more general psychiatric symptoms (SCL-
90 scores) were associated with a higher NAA/tCr ratio (r=.40, p<.05, n=32). 
 
Regional concentration ratios of the exploratory metabolites 
Concentration ratios of the ten exploratory metabolites are presented in Table S1. In the 
pgACC, CU displayed a higher glucose/tCr ratio (d=.76; Figure 3A) than HC. In the rDLPFC, CU and 
HC did not differ with regard to any metabolite concentration ratios. 
 
Correlations between drug use patterns and exploratory metabolites 
Alcohol use: In the pgACC, longer alcohol abstinence duration was associated with a higher 
NAAG/tCr ratio (r=.37, p<.05, n=31). In the rDLPFC, higher weekly alcohol use was associated with 
a higher lactate/tCr ratio (r=.44, p<.05, n=29) and a higher phosphoethanolamine/tCr ratio (r=.42, 
p<.05, n=26). None of the cocaine, cannabis or tobacco use variables were correlated with exploratory 
metabolite concentration ratios. 
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Potential Co-Factors 
Recent cocaine use: An additional ANCOVA with age, smoking status, gray matter volume, 
and white matter volume as covariates was carried out, comparing metabolite concentration ratios 
between HC (n=17), CU with a negative cocaine urine screen (n=10), and CU with a positive cocaine 
urine screen (n=8). In the pgACC, there were no significant group differences for any of the main or 
exploratory metabolite concentration ratios indicating that recent cocaine use did not measurably alter 
metabolite levels in CU (p>.05). In the rDLPFC, CU who tested positive for cocaine (mean:4893.69, 
SEM:±227.48, n=6; F(2/22)=6.35, p<.01) had increased tCho/tCr ratios compared to HC 
(3985.60±138.25, n=16, p<.05, d=1.30) and CU who tested negative for cocaine (3945.92 ±211.18, 
n=7, p<.05, d=1.34).  
Recent cannabis use: In both the pgACC and rDLPFC, main and exploratory metabolite levels 
of CU with a negative and positive urine screen for cannabis did not significantly differ from HC with 
a negative urine screen for cannabis (p>.05). 
Smoking status: Smokers and nonsmokers did not significantly differ with regard to any of the 
main and exploratory metabolites in the pgACC and rDLPFC (p>.05). 
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Discussion 
In the present study, we investigated potential glutamatergic and other neurometabolic 
alterations associated with chronic cocaine use, by using 2D JPRESS 1H-MRS combined with an 
improved quantification approach based on ProFit 2.0 and a comprehensive voxel tissue composition 
and relaxation correction approach enabling a separate quantification of glutamate and glutamine. 
Contrary to our expectation, glutamate and glutamine concentration ratios in the pgACC and rDLPFC 
did not significantly differ between CU and HC. However, higher weekly cocaine use and higher total 
concentrations of cocaine and its metabolites in the hair samples were significantly associated with 
lower glutamine concentration ratios in the pgACC indicating glutaminergic alterations in more severe 
CU. Moreover, CU exhibited significantly higher tCho concentration ratios than HC in the pgACC and 
rDLPFC and higher glucose/tCr ratios in the pACC. Finally, in the rDLPFC, CU displayed a trend for 
higher myo-inositol concentration ratios compared to HC, while in CU myo-inositol levels were 
negatively correlated with weekly cocaine use and cocaine concentration in the hair. 
 
Our non-significant group differences regarding glutamate and glutamine concentration ratios 
differ from two inconsistent prior studies with human CU: Yang et al. (2009) investigated a similar 
VOI in the bilateral pgACC of 14 chronic crack cocaine users and found a significant glutamate 
reduction (15.9%) in CU compared to HC. In contrast, Schmaal et al. (2012) reported increased 
glutamate concentrations in a more dorsal part of the left ACC. One explanation for the non-
significant group difference in the present study could be low statistical power. Alternatively, the 
varying results may also be due to different drug use patterns, abstinence durations, addiction severity, 
the selection of different portions of the ACC (dorsal vs. rostral), and methodological differences 
including the selection of different covariates and 1H-MRS acquisition and processing routines as well 
as the lack of tissue composition corrections in prior studies. For instance, the CU who participated in 
the studies of Yang et al. (2009) and Schmaal et al. (2012) all met the criteria for cocaine dependence, 
used substantially higher monthly doses of cocaine and other illegal drugs, and smoked mostly crack 
cocaine, whereas only 9 out of 18 CU of the present study met the dependence criteria, predominantly 
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administered cocaine nasally and in lower quantities, and had little co-use of other drugs. Therefore, it 
is possible that the less pronounced (poly)drug use in the present CU sample did not lead to 
measurable glutamate alterations. However, it is noteworthy that a recent study with 15 dependent CU 
also did not find significant differences of Glx concentrations between CU and HC in the striatum 
(Martinez et al. 2013). Also in contrast to the findings of Yang et al. (2009) where cocaine use 
duration correlated positively with glutamate levels, we did not find a significant correlation between 
cocaine use duration and glutamate or glutamine. Moreover, whereas Schmaal et al. (2012) found a 
negative correlation between self-reported cocaine use over the past six months and glutamate, we 
observed a negative association of self-reported weekly use of cocaine and cocaine concentrations in 
the hair samples (representing the use during the past six months) with glutamine but not glutamate in 
the pgACC. A possible explanation could be that less glutamate is taken up by glial cells and 
converted into glutamine due to down-regulated glutamate transporters as has been shown in rats after 
chronic cocaine administration (Knackstedt et al. 2010). The correlation found in our study could 
indicate that the down-regulation of glutamate transporters may be particularly pronounced in CU with 
more frequent and stronger cocaine use. However, this conjecture has to be tested in controlled animal 
studies. The fact that weekly cocaine use and cocaine concentrations in the hair samples but not 
cumulative doses or the duration of cocaine use correlated negatively with glutamine/tCr concentration 
ratios in the pgACC could suggest that recent cocaine use may be more tightly linked to glutamate-
glutamine cycling than cumulative doses and duration of use. It is noteworthy that increased glutamate 
levels have been detected in the dorsal ACC of alcohol- and opiate-dependent patients specifically 
during withdrawal (Hermann et al. 2012a; Hermann et al. 2012b). These findings indicate that the 
stage of addiction may be relevant to detect changes in Glu signals.  
 
The present study yielded higher tCho concentration ratios in the pgACC and rDLPFC of CU in 
comparison to HC, and a trend for increased myo-inositol in the rDLPFC of CU (p=.06). Our findings 
corroborate two prior studies reporting that dependent CU exhibited higher tCho levels in the PFC 
than HC (Chang et al. 1999; Meyerhoff et al. 1999). In contrast, Yang et al. (2009) did not observe 
these differences in their study. tCho is a composite measure of glycerophosphocholine, 
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phosphocholine, a small amount of free choline, and a negligible contribution from acetylcholine 
(Ross 1991). tCho is involved in membrane turnover and has been shown to be elevated in strokes, 
neoplasms, demyelination, inflammation, and gliosis (Gill et al. 1989). Myo-inositol is a pentose sugar 
putatively involved in osmoregulation, glucose storage (Ross 1991), and the calcium-mobilizing 
phosphatidylinositol second-messenger system (Berridge & Irvine 1989). Elevations in myo-inositol 
levels have been reported for low-grade brain tumors, demyelinating diseases, and Alzheimer’s 
disease and have been hypothesized to reflect glial hypertrophy or proliferation as glial cells express 
higher myo-inositol levels than neurons. Due to the vasoconstrictive effects of cocaine, CU have an 
increased risk for cerebrovascular complications (Martin-Schild et al. 2010). Potentially, elevated 
tCho and myo-inositol levels of CU may be explained by undetected hemorrhagic or ischemic micro 
strokes and hence subsequent demyelination and gliosis. 
The increased tCho and myo-inositol levels may also be in line with previous studies reporting 
marked structural alterations in chronic CU including lower white and gray matter densities in fronto-
limbic brain areas (Lyoo et al. 2004; Makris et al. 2008). Interestingly, the elevated tCho 
concentrations found in the present study were more pronounced in the rDLPFC than the pgACC. It is 
noteworthy that in a prior study, the cortical thickness of 20 dependent CU was particularly reduced in 
the rDLPFC, which also correlated with abnormal cognitive control (Makris et al. 2008). 
 
With regard to NAA, CU and HC of the present study did not significantly differ, which is in 
accordance with the findings of Yang et al. (2009) and Schmaal et al. (2012) but not with two older 
studies reporting decreased NAA levels in the PFC (Chang et al. 1999) and DLPFC of CU (Meyerhoff 
et al. 1999). NAA, one of the most abundant peptides, is primarily found in neurons, axons, and 
dendrites and is a putative marker for neuronal integrity (Simmons et al. 1991). With regard to GABA, 
CU and HC did not significantly differ in our study, which is in contrast to a prior study reporting 
reduced GABA levels in CU (Ke et al. 2004). Altogether, the fact that CU displayed increased tCho 
and myo-inositol levels particularly in the rDLPFC but no significant changes in NAA may indicate 
that astroglial signaling alterations reflected by cocaine-associated glutamine ratio reductions may be 
more prominent than perturbation of neuronal function or neuronal damage. 
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The investigated exploratory metabolites did not differ between CU and HC with exception of 
glucose. In the pgACC, glucose/tCr ratios were higher in CU compared to HC, which possibly 
indicating lower metabolic activity or glucose consumption rate. This notion would be in line with 
PET studies reporting reduced glucose metabolism in the PFC of dependent CU during protracted 
withdrawal (Volkow et al. 1992). However, changes of glucose metabolism in the ACC of CU 
measured with 1H-MRS have not been reported so far warranting further investigation. 
 
A secondary aim of the present study was to investigate the influence of potential co-factors on 
metabolite levels including the use of other legal and illegal substances and urine toxicology results. 
Our exploratory results revealed that longer alcohol abstinence was associated with higher GABA and 
NAAG concentration ratios in the pgACC, as well as lower tCho concentration ratios in the rDLPFC, 
and higher weekly alcohol use was associated with higher lactate and phosphoethanolamine levels in 
the rDLPFC. The preliminary findings of the present study may be in line with studies showing that 
initially reduced GABA and NAA levels normalized with longer alcohol abstinence (Bendszus et al. 
2001). The association between longer alcohol abstinence duration and lower tCho levels observed in 
our study is in accordance with prior findings showing that higher alcohol consumption in non-
abstinent alcohol users and in light-drinking controls was associated with higher frontal Cho levels 
(Ende et al. 2006), whereas recently detoxified and 1-month-abstinent alcohol dependent individuals 
exhibited reduced or unchanged Cho levels (Bendszus et al. 2001; Schweinsburg et al. 2000). The 
association of higher weekly alcohol use with higher lactate and phosphoethanolamine levels in the 
rDLPFC could reflect oxidative stress, hypoxia or ischemia.  
Whereas recent cocaine use did not appear to influence metabolite levels in the pgACC, in the 
rDLPFC tCho was particularly elevated in CU who had tested positive for recent cocaine use. Hence, 
we cannot fully rule out that the higher tCho/tCr concentrations at least in the rDLPFC of CU are 
partially explained by post-acute cocaine effects. Though, the elevated tCho levels in the pgACC seem 
to be unaffected by recent cocaine use. 
With regard to the clinical variables and their association with metabolite levels, we found that 
cocaine craving scores did not correlate with glutamate and glutamine levels. It is noteworthy that 
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craving scores were not very high in the present CU sample as we did not actively trigger craving. 
Additionally, a substantial part of the CU tested positive for recent cocaine use. Interestingly, we 
found that more pronounced general psychiatric symptoms were associated with higher tCho levels in 
the pgACC and higher NAA levels in the rDLPFC. These results were mainly driven by the CU 
indicating that disrupted membrane turnover and neuronal NAA metabolism may be linked to the 
development of psychiatric symptoms. 
 
A number of limitations of the present study need to be considered. First, the sample size of 36 
participants is modest, yet comparable to other 1H-MRS addiction studies. Second, the quantification 
of up to 9 of the GABA and glucose datasets exceeded CRLBs of 20% and had to be excluded from 
further analyses, decreasing the sample size and interpretability for these metabolites. Third, our CU 
sample may not have been suitable to detect glutamatergic alterations potentially induced by severe 
cocaine consumption, because only half of the CU met the criteria for cocaine dependence and overall, 
the CU of the present study used substantially less cocaine and other illegal drugs in comparison to 
CU examined in prior studies. Fourth, although we conducted additional analyses to investigate if co-
factors such as recent consumption of cocaine and cannabis have an effect on metabolite 
concentrations, we cannot fully exclude the possibility that recent drug use may have masked group 
differences. Finally, although we excluded individuals meeting the DSM-IV criteria for alcohol 
dependence and CU had relatively low cocaine craving scores, we cannot completely rule out that 
alcohol and potentially cocaine withdrawal symptoms may have upregulated prefrontal glutamate 
input, possibly accounting for the non-significant group difference and contradictory findings across 
studies. 
 
In conclusion, glutamate and glutamine concentration ratios did not significantly differ between 
CU and HC but higher weekly cocaine use and higher cocaine hair concentrations were associated 
with lower glutamine concentration ratios in the pgACC. Moreover, chronic CU exhibited 
significantly higher glucose concentration ratios in the pgACC and higher tCho concentration ratios in 
the pgACC and rDLPFC than HC. Altogether, the findings of the present study suggest that higher 
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quantity and frequency of cocaine used over the past six months appears to linearly decrease 
glutamine concentrations and that cocaine use might be associated with altered glucose metabolism 
and perturbations in membrane turnover. Future investigations should attempt to obtain a more 
complete understanding of how neurometabolic concentrations may differ between different stages of 
cocaine addiction. Moreover, 13C-MRS could provide valuable information with regard to 
compartmental glutamate-glutamine changes in neurotransmitter and metabolic pools. Lastly, applying 
1H-MRS in the NAc of human CU would be of particular interest, allowing a more direct investigation 
of the translational value of animal addiction models. 
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Titles and legends to figures 
 
Figure 1. Prototypical projections of 2D J-PRESS 1H magnetic resonance spectroscopy spectra 
acquired in the bilateral pregenual anterior cingulate cortex (A) and the right dorsolateral prefrontal 
cortex (B) of a healthy control subject. The red lines represent the model fit, the blue lines the data, 
and the green lines the residual fit. mI, myo-inositol; Cho, choline; Cr, creatine; Gln, glutamine; Glu, 
glutamate; NAA, N-acetylaspartate. 
 
Figure 2. A simulated in vivo 2D JPRESS spectrum from the pregenual anterior cingulate cortex 
voxel, the spectral fit, and the fit residue are presented.  
 
Figure 3. (A) Scatterplots of glucose/total creatine ratios measured in the bilateral pregenual anterior 
cingulate cortex of 10 healthy controls and 16 cocaine users. The mean (indicated by the bar)  SD 
was 5939.521885.42 and 7311.202240.28, respectively. (B) Scatterplots of total choline/total 
creatine ratios measured in the right dorsolateral prefrontal cortex of 18 healthy controls and 13 
cocaine users. The mean (indicated by the bar)  SD was 3832.61406.02 and 4510.87863.93, 
respectively. 
 
Figure 4. (A) Scatterplots of glutamate/total creatine ratios measured in the bilateral pregenual 
anterior cingulate cortex of 17 healthy controls and 18 cocaine users. The mean (indicated by the bar) 
 SD was 32300.81 6672.97 and 33045.94 10161.92, respectively. (B) Scatterplots of 
glutamate/total creatine ratios measured in the right dorsolateral prefrontal cortex of 18 healthy 
controls and 13 cocaine users. The mean  SD was 36746.11 8876.64 and 40117.84 9783.55, 
respectively. (C) Scatterplots of glutamine/total creatine ratios measured in the bilateral pregenual 
anterior cingulate cortex of 17 healthy controls and 17 cocaine users. The mean (indicated by the bar) 
 SD was 6494.12 1853.79 and 6761.57 1504.29, respectively. (D) Scatterplots of glutamine/total 
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creatine ratios measured in the right dorsolateral prefrontal cortex of 17 healthy controls and 13 
cocaine users. The mean  SD was 5920.72 2012.34 and 7048.24 2472.53, respectively. 
 
Figure 5. Correlations between drug use variables and metabolite/total creatine ratios. Higher weekly 
cocaine use in grams and higher cocaine concentrations in the hair samples (pg/mg) were associated 
with lower glutamine/total creatine ratios in the pregenual anterior cingulate cortex (A and B) and 
lower myo-inositol/total creatine ratios in the dorsolateral prefrontal cortex of cocaine users (C and D). 
 
 
 
 
 
 
 
Table 1. Demographic data and legal drug consumption (means and standard deviations, number of subjects and percent) 
 
  Controls (n=18) Cocaine users (n=18) Valuea pa df 
Age 35.78 (±8.32) 36.17 (±7.64) -0.15 0.89 34 
Body Mass Index (kg/m2) 23.81 (±2.72) 25.09 (±3.51) -1.22 0.23 34 
Years of education 10.67 (±1.97) 10.50 (±1.89) 0.26 0.80 34 
Beck Depression Inventory 5.28 (±6.48) 5.89 (±3.91) -0.34 0.73 34 
SCL-90-R Global Severity Index 0.29 (±0.41) 0.38 (±0.24) -0.77 0.45 34 
Cocaine Craving Questionnaire (sum) - 20.06 (±6.03) - - - 
Smoking Status (yes/no) 12, 6 (67, 33%) 13, 5 (72, 28%) 0.13b 0.72b 1 
FTND (sum) 2.83 (±2.79) 4.85 (±3.21) -1.67 0.11 23 
      
Alcohol use      
Grams per week 109.37 (±108.95) 262.00 (±251.48) -2.36 0.03 34 
Years of use 17.22 (±8.61) 17.58 (±6.46) -0.14 0.89 34 
Age of alcohol onset 18.56 (±5.75) 18.58 (±4.03) -0.02 0.99 34 
Last consumption (days) 7.67 (±13.69) 3.54 (±4.57) 1.22 0.24 34 
      
Tobacco use      
Cigarettes per week 58.92 (±64.45) 85.19 (±73.74) -1.11 0.28 34 
Years of use 11.53 (±10.80) 12.06 (±9.18) 0.26 0.80 34 
Age of smoking onset 24.25 (±10.72) 25.50 (±12.05) -0.33 0.74 34 
Last consumption (hours) 13.33 (±21.68) n=12 123.86 (±320.35) n=13 -1.24 0.24 23 
aIndependent T-test, bChi2-test for frequency data. SCL-90-R, Symptom Check List 90-R; FTND, Fagerström Test for Nicotine 
Dependence. 
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Table 2. Illegal drug use patterns (means and standard deviations) 
  Controls (n=18)  Cocaine users (n=18) 
   
Cocaine   
  Times per week 0.00 (±0.00) 1.28 (±1.39) 
  Grams per week 0.00 (±0.00) 1.46 (±1.36) 
  Years of use 0.00 (±0.00) 10.14 (±5.55) 
  Age of cocaine use onset - 26.03 (±6.32) 
  Cumulative dose (grams) 0.00 (±0.00) 1056.56 (±977.50) 
  Last consumption (days) - 7.60 (±6.84) 
  Total cocaine in hair (pg/mg) 0.00 (±0.00) 22770 (±23560) 
  Ethylcocaine in hair (pg/mg) 0.00 (±0.00) 1490 (±2710) 
  Urine toxicology (pos./neg.) 0, 100 (0, 100%) 8, 10 (44, 56%) 
   
Cannabis   
  Grams per week 0.15 (±0.42) 1.07 (±1.92) 
  Years of use 4.69 (±7.37) 7.83 (±8.67) 
  Age of cannabis onset 31.08 (±9.82) 28.33 (±11.25) 
  Cumulative dose (grams) 171.30 (±283.25) 1563.85 (±2689.90) 
  Last consumption (days) 50.76 (±74.39) n=5 3.81 (±2.14) n=8 
  Urine toxicology (pos./neg.) 2, 16 (13, 89%) 6, 12 (33, 67%) 
   
Amphetamine   
  Grams per week 0.00 (±0.00) 0.0043 (±0.01) 
  Years of use 0.00 (±0.00) 0.64 (±1.30) 
  Cumulative dose (grams) 0.00 (±0.00) 10.77 (±25.86) 
  Last consumption (days) - 76.00 (±40.22) n=3 
  Amphetamine in hair (pg/mg) 0.00 (±0.00) 12 (±30) n=3 
  Methamphetamine in hair (pg/mg) 0.00 (±0.00) 0.00 (±0.00) 
   
MDMA   
  Pills per week 0.00 (±0.00) 0.03 (±0.06) 
  Years of use 0.00 (±0.00) 3.58 (±4.94) 
  Cumulative dose (pills) 0.00 (±0.00) 24.88 (±63.74) 
  Last consumption (days) - 70.63 (±47.67) n=7 
  MDMA in hair (pg/mg) 0.00 (±0.00) 1644 (±4859) n=6 
  MDA in hair (pg/mg) 0.00 (±0.00) 68 (±259) n=2 
Consumption per day/week captures the past six months, duration of use and cumulative 
dose are averaged within the total group. Last consumption is averaged only for subjects 
who used the drug in the past six months. In this case, sample size is shown. The hair 
analysis was performed on two hair samples (each 3 cm in length) per participant capturing 
drug use over the past six months. Concentrations were averaged over the two samples. If 
the hair sample was not long enough, only one sample was analyzed (3 cm, 3 months). 
MDMA, 3,4-methylenedioxy-N-methylamphetamine; MDA, 3,4-
methylenedioxyamphetamine.
Table 3. Tissue composition and 1H-MRS metabolite/total creatine ratios (means and standard errors) 
  Pregenual Anterior Cingulate Cortex   Dorsolateral Prefrontal Cortex 
  Controls (n=17) Cocaine users (n=18) T/F value p value df/dferr   Controls (n=18) Cocaine users (n=13) T/F value p value df/dferr 
            
Tissue composition %a            
Gray matter 69.57 (±0.90) 68.63 (±1.18) 0.63 0.54 33  53.92 (±1.13) 51.11 (±1.49) 1.54 0.14 29 
White matter 11.89 (±0.50) 11.43 (±0.74) 0.51 0.61 33  36.03 (±2.13) 40.02 (±2.33) -1.25 0.22 29 
Cerebrospinal fluid 18.35 (±0.81) 19.68 (±1.13) -0.94 0.35 33  7.54 (±0.89) 7.29 (±1.56) 0.15 0.88 29 
            
Metabolitesb            
Total creatinec 7.33 (±0.15) 7.16 (±0.15) 0.66 0.43 1/29  6.43 (±0.15) 6.39 (±0.18) 0.04 0.85 1/25 
Glutamate 32703.44 (±2094.89) 32665.67 (±2034.50) 0.00 0.50 1/29  37588.31 (±2342.15) 38951.72 (±2790.62) 0.13 0.36 1/25 
Glutamine 6483.22 (±400.69) 6772.47 (±400.69) n=17 0.25 0.31 1/28  6196.01 (±555.94) n=17 6688.24 (±642.72) 0.31 0.29 1/24 
N-acetylaspartate 27275.94 (±1053.25) 27292.15 (±1022.89) 0.00 0.50 1/29  33096.86 (±1230.14) 34973.83 (±1465.69) 0.90 0.18 1/25 
Total choline 4748.84 (±129.74) 5057.53 (±126.00) 2.85 0.05 1/29  3902.68 (±149.55) 4413.85 (±178.18) 4.49 0.02 1/25 
γ-aminobutyric acid 3748.31 (±551.07) n=10 3856.42 (±584.03) n=9 0.02 0.45 1/13  5924.69 (±1039.13) n=13 4125.94 (±1286.96) n=9 1.02 0.17 1/16 
Myo-inositol 18058.59 (±636.51) 18509.53 (±618.16) 0.25 0.31 1/29   16408.44 (±1439.02) 20170.85 (±1714.57) 2.63 0.06 1/25 
aUnpaired T-test, bANCOVA with age, smoking status, gray matter volume, and white matter volume as covariates (one-tailed tests), creferenced to H2O.  
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Materials and methods 
 
Participants were recruited through advertisements in local newspapers, internet platforms, drug 
prevention and treatment centers, psychiatric hospitals, and word-of-mouth communication (for details 
see Hulka et al. 2014). 
 
Reference 
Hulka LM, Treyer V, Scheidegger M, Preller KH, Vonmoos M, Baumgartner MR, Johayem A, Ametamey SM, Buck A, Seifritz 
E, Quednow BB (2014) Smoking but not cocaine use is associated with lower cerebral metabotropic glutamate receptor 5 
density in humans. Mol Psychiatry 19:625-632.
Table S1. 1H-MRS exploratory metabolite ratios with total creatine as reference (means and standard errors) 
  Pregenual Anterior Cingulate Cortex  Dorsolateral Prefrontal Cortex 
  Controls (n=17)  Cocaine users (n=18) F value p value df/dferr  Controls (n=18)  Cocaine users (n=13) F value p value df/dferr 
            
NAAG 2248.87 (±281.35) n=16 2306.39 (±291.31) n=15 0.02 0.89 1/25  2457.92 (±280.11) n=16 2759.74 (±345.63) n=11 0.41 0.53 1/21 
Glucose 5758.06 (±582.98) n=10 7424.61 (±456.85) n=16 4.89 0.04 1/20  6397.05 (±513.13) n=10 6252.20 (±544.73) n=9 0.03 0.86 1/13 
Lactate 4249.38 (±453.24) n=16 4354.46 (±439.31) n=17 0.03 0.87 1/27  5421.22 (±900.57) 8372.97 (±1100.21) n=12 3.76 0.07 1/23 
Scyllo-inositol 1887.50 (±151.20)  1749.34 (±146.84) 0.42 0.52 1/29  1655.29 (±174.36) 1854.44 (±207.75) 0.50 0.49 1/25 
Taurine 6184.27 (±389.12) n=16 5313.87 (±377.23) n=17 2.52 0.12 1/27  5414.22 (±372.39) n=16 5997.27 (±435.55) n=12 0.95 0.34 1/22 
Glycine 3373.96 (±329.02) 3067.60 (±329.02) n=17 0.43 0.52 1/28  3319.16 (±246.08) n=16 2988.60 (±318.04) n=10 0.62 0.44 1/20 
Glutathione  7866.46 (±462.55) 7982.70 (±449.21) 0.03 0.86 1/29  7684.90 (±601.11) 8671.42 (±716.21) 1.04 0.32 1/25 
Phosphoethanolamine  6044.10 (±833.35) n=14 7329.40 (±833.35) n=14 1.18 0.29 1/22  7210.72 (±788.07) n=15 7460.75 (±940.21) n=11 0.04 0.85 1/20 
Aspartate 11572.12 (±868.96) 11440.43 (±843.90) 0.01 0.92 1/29  15616.44 (±1016.73) 15164.99 (±1211.41) 0.08 0.79 1/25 
Ascorbic acid 8191.57 (±526.91) 8825.12 (±511.72) 0.73 0.40 1/29  6734.61 (±656.26) 8358.91 (±781.92) 2.36 0.14 1/25 
ANCOVA with age, smoking status, grey matter volume, and white matter volume as covariates. NAAG, N-acetylaspartylglutamate. 
 
 
 
 
Table S2. 1H-MRS metabolite ratios with H2O as reference (means and standard errors) 
  Pregenual Anterior Cingulate Cortex  Dorsolateral Prefrontal Cortex 
  Controls (n=17) Cocaine users (n=18) T/F value p value df/dferr  Controls (n=18)  Cocaine users (n=13) T/F value p value df/dferr 
            
Glutamate 8.73 (±0.52) 8.46 (±0.50) 0.14 0.36 1/29  8.99 (±0.48) 8.81 (±0.58) 0.05 0.41 1/25 
Glutamine 1.73 (±0.11) 1.77 (±0.11) n=17 0.09 0.39 1/28  1.49 (±0.13) n=17 1.53 (±0.16) 0.03 0.44 1/24 
NAA 7.25 (±0.14) 7.07 (±0.14) 0.74 0.20 1/29  7.89 (±0.15) 7.90 (±0.18) 0.00 0.49 1/25 
Total choline 1.27 (±0.04) 1.33 (±0.04) 1.26 0.14 1/29  0.93 (±0.02) 1.00 (±0.03) 3.74 0.04 1/25 
GABA 0.99 (±0.17) n=10 1.09 (±0.18) n=9 0.16 0.35 1/13  1.36 (±0.21) n=13 0.94 (±0.27) n=9 1.31 0.14 1/16 
myo-inositol 4.81 (±0.12) 4.83 (±0.12) 0.02 0.45 1/29  3.93 (±0.29) 4.52 (±0.35) 1.56 0.11 1/25 
NAAG 0.57 (±0.06) n=16 0.06 (±0.06) n=15 0.09 0.77 1/25  0.58 (±0.06) n=16 0.62 (±0.08) n=11 0.16 0.70 1/21 
Glucose 1.44 (±0.14) n=10 1.97 (±0.11) n=16 7.94 0.01 1/20  1.45 (±0.08) n=10 1.43 (±0.08) n=9 0.03 0.87 1/13 
Lactate 1.12 (±0.12) n=16 1.14 (±0.12) n=17 0.01 0.93 1/27  1.29 (±0.21) n=17 1.95 (±0.25) n=12 3.69 0.07 1/23 
Scyllo-inositol  0.50 (±0.04) 0.46 (±0.04) 0.61 0.44 1/29  0.39 (±0.04) 0.41 (±0.04) 0.07 0.79 1/25 
Taurine 1.68 (±0.12) n=16 1.39 (±0.12) n=17 2.71 0.11 1/27  1.30 (±0.08) n=16 1.35 (±0.10) n=12 0.10 0.75 1/22 
Glycine 0.91 (±0.10) 0.84 (±0.10) n=17 0.27 0.61 1/28  0.80 (±0.06) n=16 0.70 (±0.08) n=10 0.88 0.36 1/20 
Glutathione  2.12 (±0.15) 2.11 (±0.14) n=18 0.00 0.95 1/29  1.84 (±0.12) 1.94 (±0.15) 0.30 0.59 1/25 
Phosphoethanolamine  1.59 (±0.24) n=14 1.99 (±0.24) n=14 1.40 0.25 1/22  1.68 (±0.17) n=15 1.66 (±0.20) n=11 0.00 0.95 1/20 
Aspartate 3.10 (±0.22) 2.99 (±0.22) 0.11 0.75 1/29  3.76 (±0.22) 3.40 (±0.27) 0.97 0.33 1/25 
Ascorbid acid 2.18 (±0.15) 2.32 (±0.14) 0.43 0.52 1/29  1.62 (±0.13) 1.88 (±0.16) 1.41 0.25 1/25 
ANCOVA with age, smoking status, grey matter volume, and white matter volume as covariates. NAA, N-acetylaspartate; GABA, γ-aminobutyric acid; mI, myo-inositol; NAAG, 
N-acetylaspartylglutamate. 
 
 
